COMPARISON OF THE EFFECT OF DISTAL ADDUCTOR CANAL BLOCK COMBINED WITH GENICULAR NERVE BLOCK OR PERIARTICULAR INJECTION ON POSTOPERATIVE QOR-15 IN TOTAL KNEE ARTHROPLASTIES
NCT ID: NCT07077720
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2025-01-30
2025-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods: Sixty patients received spinal anesthesia and distal ACB, then were randomized to GNB (Group G, n=30) or PAI (Group P, n=30). QoR-15, morphine consumption, VAS pain scores, nausea/vomiting, and side effects were evaluated.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Pain Relief After Arthroscopic Knee Surgery: Adductor Canal Block and Genicular Nerve Block
NCT06909851
Efficacy of Peripheral Nerve Blocks in Total Knee Arthroplasty
NCT07040709
Supplementary Nerve Blocks Added to the Adductor Canal Block for Postoperative Pain Management in Primary Total Knee Arthroplasty: A Randomized Controlled Comparison of Sciatic, BiFeS, and IPACK Techniques
NCT07242170
Postoperative Analgesic Efficacy Between Adductor Canal Block + IPACK Block and Adductor Canal Block + Genicular Nerve Block in Total Knee Arthroplasty
NCT07324486
Comparison Ultrasound-Guided Adductor Canal Block and Surgeon-Performed Block for Pain Management After Total Knee Arthroplasty
NCT06533085
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Materials and Methods: This single-center, randomized, prospective study included patients over 18 years of age with ASA physical status I-III who were scheduled for total knee arthroplasty under spinal anesthesia. All patients received spinal anesthesia with 15 mg isobaric bupivacaine combined with 100 mcg intrathecal morphine. Additionally, all patients underwent ultrasound-guided distal adductor canal block. Patients were randomized into Group G (n=30) and Group P (n=30). Group G received preoperative genicular nerve block (5+5+5 ml of 0.25% bupivacaine), whereas Group P received intraoperative periarticular injection administered by the surgical team, consisting of 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin and 110 mg bupivacaine. The primary outcome measure was the quality of recovery evaluated by the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours postoperatively. Secondary outcomes included morphine consumption at 2., 6., 12. and 24 hours postoperatively, resting and movement Visual Analog Scale (VAS) pain scores, postoperative nausea and vomiting (PONV) scores, and the incidence of adverse effects such as respiratory depression, urinary retention, and pruritus.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Grup G
Genicular nerve block
genicular nerve block
genicular nerve block with a total of 15 mL of 0.25% bupivacaine preoperatively
Addukctor canal block
Addukctor canal block with 15ml %0.25 bupivacaine
Spinal Anesthesia with Bupivacaine and Morphine
Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
Grup P
Periarticular injecrion
periarticular injection
periarticular injection prepared by the surgical team containing 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin, and 110 mg bupivacaine.
Addukctor canal block
Addukctor canal block with 15ml %0.25 bupivacaine
Spinal Anesthesia with Bupivacaine and Morphine
Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
genicular nerve block
genicular nerve block with a total of 15 mL of 0.25% bupivacaine preoperatively
periarticular injection
periarticular injection prepared by the surgical team containing 8 mg morphine, 40 mg methylprednisolone, 0.3 mg adrenaline, 750 mg cefazolin, and 110 mg bupivacaine.
Addukctor canal block
Addukctor canal block with 15ml %0.25 bupivacaine
Spinal Anesthesia with Bupivacaine and Morphine
Spinal Anesthesia with Bupivacaine(isobaris 15-18mg) and Morphine(100mcg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients classified as ASA I, II, or III
* Patients aged 18 years and older
Exclusion Criteria
* Presence of infection near the puncture site
* History or presence of neurological disorders (e.g., transient ischemic attack, syncope, dementia, etc.)
* Known coagulation disorders
* History of alcohol or substance abuse
* Impaired consciousness
* Chronic opioid use equal to or exceeding 60 mg of oral morphine equivalents per day
* Pre-existing neuropathic pain
* Hepatic failure, renal failure, or cardiac insufficiency
* Uncontrolled diabetes mellitus
* Pregnant or breastfeeding women
* Refusal or inability to provide written informed consent
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bezmialem Vakif University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammed Çağrı Sarıarslan
research assistant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bezmialem vakıf üniversitesi
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
29.01.2025-E.180706
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.